Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms

NCT00229645 is registered in ClinicalTrials.gov with Dr Alexander McIntyre Inc. as lead sponsor.

NCT NCT00229645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00229645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms
Lead sponsor
Dr Alexander McIntyre Inc.
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2003
Completion date
April 30, 2005
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depression with comorbid anxiety symptoms